Partnering and Networking Opportunities Abound at BIO-Windhover Conference


WASHINGTON, D.C. (April 2, 2007) -- The Biotechnology Industry Organization (BIO) and Windhover Information Inc. are once again joining together to host the 6th Annual BIO-Windhover Conference – The Partnering Conference for Decision Makers, April 9-11, 2007 at the Ritz-Carlton, Washington, D.C.  The BIO-Windhover Conference provides exclusive partnering opportunities for top-level pharmaceutical and biotechnology business development executives and CEOs.

“This event provides a truly exclusive opportunity for senior level executives to meet one-on-one with other key decision-makers and network with their peers for a more personal experience in an upscale setting,” stated Alan Eisenberg, executive vice president, Emerging Companies & Business Development at BIO.

Using the conference’s unique partnering software, attendees will have the opportunity to quickly identify and schedule meetings with prospective partners to discuss and negotiate deals or search company and delegate profiles and a database of licensing opportunities.   This year’s participants to date include delegations from Amgen, AstraZeneca, Biogen IDEC, Boehringer Ingelheim, Bristol-Myers Squibb Co., Celera Genomics, Eisai, Eli Lilly & Co., Forest Laboratories, GlaxoSmithKline, Human Genome Sciences, Johnson & Johnson, LG Life Sciences, Merck, Otsuka Pharmaceutical, Pfizer Inc., Roche, Schering-Plough Corp., Takeda, and Wyeth, among others.

The event will also feature two industry related plenary sessions.  On Tuesday, April 10, Windhover Information’s Managing Partner Roger Longman will moderate the panel session, “Hot In-Licensing Deals and the Rationale Behind Them.”  The panelists will be: Alan Crane, President & CEO, Tempo Pharmaceuticals, Inc., Denise Goode, Executive Transaction Director, Strategic Planning & Business Development, AstraZeneca, Annarie Lyles, Ph.D., Senior Vice President, Head of Business Development, Genmab, Kumar Srinivasan, Ph.D., MBA, Assistant Vice President, Licensing, Global Business Development, Wyeth Pharmaceuticals, Barbara Yanni, Vice President & Chief Licensing Officer, Merck & Co., Inc. 

Wednesday’s session, “Key Mergers and Acquisition Strategies that Reveal the New Order,” will be moderated by Alan Eisenberg, Executive Vice President, Emerging Companies & Business Development, BIO. The panelists will be: Nicholas Galakatos, Ph.D., Co-Founder & Managing Director, Clarus Ventures, LLC, Jason Levin, Vice President, Licensing & Acquisitions, Jazz Pharmaceuticals Inc., Jeffrey A. Meckler, Executive Director, Worldwide Business Development, Pfizer Inc., George J. Milstein, Head of Investment Banking, Pacific Growth Equities, LLC, Thomas Shoaf, M.D., Senior Director, Global Licensing and Business Development, UCB.

For more information on the 6th Annual BIO-Windhover Conference, please visit


About Windhover Information Inc.
Windhover Information Inc. is the leading provider of superior analysis and commentary on health care business strategy, deal rationale, marketplace trends, and the world of medical start-ups since 1989. Windhover provides objective, quality content through conferences, publications, reports and databases researched from the pharmaceutical, biotech, medical device and diagnostic industries as well as in the investment banking, venture capital, consulting and other industry-support sectors.


About BIO
BIO represents more than 1,100 biotechnology companies, academic institutions, state biotechnology centers and related organizations across the United States and 31 other nations. BIO members are involved in the research and development of healthcare, agricultural, industrial and environmental biotechnology products. BIO also produces the annual BIO International Convention, the world’s largest biotechnology conference and exhibition.

Upcoming BIO Events

BIO-Windhover Conference
April 9-11, 2007
Washington, D.C.

BIO International Convention
May 6-9, 2007
Boston, MA

BIO VentureForum-East 2007
June 18-20, 2007
Montreal, Canada